The U.S. Food and Drug Administration (FDA) has cleared artificial intelligence (AI) firm Vysioneer's brain tumor autocontouring software, called VBrain.
VBrain maps three types of brain tumors -- metastasis, meningioma, and acoustic neuroma -- allowing patients to begin radiation therapy more quickly than when contouring must be performed manually, the company said.
VBrain applies autocontouring to the three most common types of brain tumors: brain metastasis, meningioma, and acoustic neuroma. Image courtesy of Vysioneer.In an 18-month clinical trial conducted at the National Taiwan University Hospital in Taipei, researchers found that VBrain had a 12.2% higher sensitivity for detecting lesions compared with manual contouring, and it decreased treatment planning time by 30.8%, Vysioneer said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
